# Navitor Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/navitor-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Cambridge, US
- Website: www.navitorpharma.com
- Total disclosed funding: $67M
- Latest round: Series B (Dec 18, 2015)
- Investors on record: 8

## About

Navitor Pharmaceuticals, Inc. is a biotechnology company dedicated to developing innovative therapeutic solutions to address unmet medical needs, focusing on metabolic diseases such as obesity and diabetes.Founded in 2010 and headquartered in Cambridge, US, Navitor Pharmaceuticals, Inc. specializes in innovative treatments for metabolic disorders. The company has engaged in 5 deals, the most recent being in December 2018, when it raised USD 11.25 mn in venture funding. Jun Hu serves as CEO, guiding the company's strategic initiatives.Navitor Pharmaceuticals focuses on developing proprietary compounds that modulate cellular metabolism to treat metabolic disorders, including obesity and diabetes. Their products target specific biochemical pathways, serving healthcare providers, research institutions, and pharmaceutical partners primarily in North America and parts of Europe.Navitor Pharmaceuticals generates revenue through partnerships and collaborations with biopharmaceutical companies, as well as direct sales of therapeutic products. Revenue streams include licensing agreements that yield milestone payments and royalties, alongside B2B transactions with healthcare providers and potential direct-to-consumer sales.Navitor Pharmaceuticals intends to leverage the USD 11.25 mn raised in December 2018 to advance its pipeline of metabolic disorder treatments. The company is focusing on launching new products designed to enhance metabolic responses and plans to expand its market presence into additional regions in Europe by 2025.

## Funding rounds

- Series B, Dec 18, 2015, $33M — Atlas Venture, Polaris Partners, SR One, Johnson & Johnson Innovation, Sanofi Ventures, Remeditex Ventures, Brace Pharma Capital
- Series A, Jun 19, 2014, $24M — Atlas Venture, Polaris Partners, SR One, Johnson & Johnson Innovation, The Longevity Fund
- Series A, Sep 19, 2013, $10M — Polaris Partners

## Investors

- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series A, Series B
- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series A, Series B
- SR One (https://capitalatlas.ai/funds/sr-one) — Series A, Series B
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series A, Series B
- The Longevity Fund (https://capitalatlas.ai/funds/the-longevity-fund) — Series A
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series B
- Remeditex Ventures (https://capitalatlas.ai/funds/remeditex-ventures) — Series B
- Brace Pharma Capital (https://capitalatlas.ai/funds/brace-pharma-capital) — Series B